Epitalon peptide: the telomere guide

Key takeaways

• Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the pineal gland’s epithalamin extract
• It is the only peptide with published data showing direct telomerase activation and telomere elongation in human cell lines
• Nearly all research comes from one lab group (Khavinson and colleagues) at the St. Petersburg Institute of Bioregulation and Gerontology
• No human clinical trials have been completed or registered as of 2026
• Epitalon is not FDA-approved and is only available through compounding pharmacies or research suppliers

What is epitalon?

Epitalon is a four-amino-acid peptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was first synthesized by Russian gerontologist Vladimir Khavinson as a synthetic version of epithalamin, a polypeptide extract from bovine pineal glands. Khavinson’s team identified the AEDG sequence within the pineal gland’s polypeptide complex in 2017 [1].

The peptide sits at the center of an unusual anti-aging hypothesis: that short peptides produced by the pineal gland regulate telomerase activity, and that supplementing them can slow or reverse cellular aging. This is a narrow but testable claim, and the cell culture data supporting it is more concrete than what most anti-aging peptides can offer.

Within peptide therapy, epitalon occupies a unique niche. While peptides like BPC-157 target tissue repair and GHK-Cu focuses on skin remodeling, epitalon addresses one of the most fundamental mechanisms of aging: telomere shortening.

How does epitalon work?

Every time a cell divides, its telomeres get shorter. Once they reach a critical length, the cell stops dividing and enters senescence. Telomerase, an enzyme that adds DNA repeats back to telomere ends, can counteract this process. Most adult human cells produce little or no telomerase.

Epitalon appears to reactivate telomerase in cells that have stopped producing it. In a 2003 study, Khavinson’s group treated human fetal lung fibroblasts and adult retinal pigment epithelium cells with epitalon (10 nM) and observed increased telomerase activity alongside measurable telomere elongation [2]. A follow-up study in 2004 showed that fibroblasts treated with epitalon exceeded the Hayflick limit (the normal maximum division count for human somatic cells), with treated cells reaching 44 population doublings compared to 34 in controls [3].

The mechanism likely involves epigenetic regulation. A 2020 study found that epitalon stimulated gene expression related to neurogenesis and protein synthesis in human dental pulp stem cells, suggesting the peptide may interact with chromatin structure and gene promoters rather than a single receptor [4]. In cell culture, epitalon has been shown to interact with specific DNA sequences in gene promoter regions [5].

A 2025 study published in Biogerontology provided the most detailed confirmation to date. Al-Dulaimi et al. found that epitalon increased telomere length in multiple human cell lines, working through telomerase upregulation in some cells and alternative lengthening of telomeres (ALT) pathways in others [6]. This suggests the peptide’s effects may be more versatile than originally thought.

Benefits supported by research

Telomere lengthening

The primary evidence for epitalon comes from cell culture studies. In Khavinson’s 2003 experiment, epitalon treatment increased telomere length by approximately 33% in fetal fibroblasts over 13 passages [2]. The 2025 study by Al-Dulaimi confirmed these findings with more rigorous methodology, showing telomere elongation across different cell types [6].

Extended cellular lifespan

Cells treated with epitalon divided more times before senescence. In the 2004 study, treated cells continued dividing 10 passages beyond the point where control cells stopped, representing a roughly 29% extension of replicative lifespan [3].

Neurogenesis support

Khavinson’s 2020 research showed epitalon stimulated gene expression and protein synthesis during neuronal differentiation of stem cells [4]. A separate 2019 study confirmed that short peptides including AEDG promoted neuronal differentiation of dental pulp stem cells into neural-like cells [7].

Skin cell effects

In vitro studies have shown epitalon affects skin fibroblast behavior during aging. A 2016 study found the peptide regulated markers of fibroblast function in aging cell cultures [8]. A 2014 study demonstrated that short peptides including epitalon stimulated skin cell regeneration in tissue cultures from elderly donors [9].

Pineal gland function

Because epitalon was derived from pineal extracts, some researchers have suggested it may support melatonin production and circadian function. However, this specific claim lacks direct experimental evidence in human studies. The connection between pineal-derived peptides and aging markers was reviewed by Khavinson et al. in 2014, though the data remained preliminary [10].

Side effects and safety

Epitalon has a limited safety profile because no controlled human trials have been conducted. The available information comes from cell culture experiments and anecdotal reports from people who have self-administered the peptide.

Cell culture studies at concentrations of 10 nM to 20 nM have not reported cytotoxicity [2, 6]. The peptide’s small size (four amino acids) makes allergic reactions unlikely, though not impossible.

Commonly reported side effects from anecdotal use include injection site reactions (redness, minor swelling) and temporary changes in sleep patterns. Some users report vivid dreams, which could relate to the peptide’s pineal gland origins, though this is speculative.

The bigger safety concern is theoretical: telomerase activation also occurs in cancer cells. Whether exogenous telomerase activation could promote tumor growth remains an open question. The 2025 Al-Dulaimi study noted this concern but found no evidence of malignant transformation in treated cells over their observation period [6]. For context, whether peptides can cause cancer is a broader question with nuanced answers.

Anyone considering epitalon should discuss it with a physician familiar with peptide therapy and understand that the evidence base remains preclinical.

Dosage and administration

No dosage has been validated in clinical trials. The following protocols come from practitioner reports and the research community:

Common injectable protocols call for 5-10 mg administered subcutaneously, typically in 10-day cycles repeated 2-3 times per year. Some practitioners use lower daily doses of 1-3 mg during the cycle period.

The peptide requires reconstitution with bacteriostatic water and subcutaneous injection. For those unfamiliar with the process, our guide on how to inject peptides covers the basics.

These are not medical recommendations. They reflect what circulates in the clinical peptide therapy community and should only be pursued under physician supervision through a peptide therapy clinic.

Research and clinical trials

The Khavinson body of work

Nearly all published epitalon research traces back to Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. This is both the peptide’s strength and its weakness. The group has published consistently for over two decades, building a coherent body of work. But independent replication has been slow.

Khavinson’s earlier work with epithalamin (the crude pineal extract) included animal longevity studies showing extended lifespan in rodents. The synthetic AEDG peptide was developed to isolate the active component, with the AEDG sequence confirmed in pineal extracts in 2017 [1].

Independent confirmation

The 2025 study by Al-Dulaimi et al. represents the first significant independent confirmation of epitalon’s telomere effects [6]. Published in Biogerontology (a peer-reviewed journal with an impact factor of ~4.5), it used modern methodology including quantitative fluorescence in situ hybridization (Q-FISH) and telomere restriction fragment analysis. The authors confirmed telomere elongation but also identified the ALT pathway as a secondary mechanism, adding complexity to the original telomerase-only hypothesis.

What’s missing

No registered clinical trials for epitalon appear in ClinicalTrials.gov as of April 2026. The leap from in vitro telomere elongation to meaningful anti-aging effects in living humans remains unproven. Telomere length is associated with aging in population studies, but whether artificially lengthening telomeres translates to health benefits is genuinely unknown.

Among the peptides studied for anti-aging, epitalon has the most direct mechanistic data. But direct mechanism data without clinical trials is not the same as clinical evidence.

How to get epitalon

Epitalon is not FDA-approved for any indication. It is not available through standard pharmacies.

Access routes include compounding pharmacies that prepare it as a research peptide, and international peptide suppliers. The legal status of peptides varies by country, but in the United States, epitalon falls into a regulatory gray area as an unscheduled research chemical.

For those interested in medically supervised peptide protocols, a peptide therapy consultation with a physician experienced in anti-aging medicine is the safest starting point. Our list of peptides covers other compounds with stronger clinical evidence that may serve similar goals.

Frequently asked questions

What does epitalon actually do?▼

Epitalon activates telomerase, the enzyme that rebuilds telomere caps on chromosomes. In cell culture studies, this leads to longer telomeres and extended cellular lifespan. Whether these effects translate to anti-aging benefits in living humans has not been tested in clinical trials.

Is epitalon the same as epithalamin?▼

No. Epithalamin is a crude polypeptide extract from bovine pineal glands. Epitalon (AEDG) is a specific synthetic four-amino-acid peptide identified within that extract. Epitalon is more consistent, easier to manufacture, and better characterized than the original extract.

How long does an epitalon cycle last?▼

Most practitioner protocols use 10-day cycles of daily injections (5-10 mg subcutaneously), repeated 2-3 times per year. These protocols are not based on clinical trial data.

Can epitalon cause cancer?▼

Telomerase activation is a hallmark of cancer cells, so the question is reasonable. No published study has shown epitalon promoting cancer, and the 2025 Al-Dulaimi study specifically monitored for malignant transformation without observing it [6]. But the absence of evidence is not evidence of absence, and long-term safety data does not exist.

Is epitalon legal?▼

In the US, epitalon is not a scheduled substance but is also not FDA-approved. It exists in a regulatory gray area similar to many research peptides. Purchasing for personal use is generally not prosecuted, but it cannot be legally marketed as a drug or supplement.

How is epitalon different from other anti-aging peptides?▼

Most anti-aging peptides work indirectly, through growth hormone secretion (sermorelin, CJC-1295/ipamorelin), antioxidant activity (GHK-Cu), or mitochondrial function (MOTS-c). Epitalon is the only one with published data showing direct telomerase activation and telomere elongation in human cells.

Who discovered epitalon?▼

Vladimir Khavinson, a Russian gerontologist at the St. Petersburg Institute of Bioregulation and Gerontology, developed epitalon as a synthetic derivative of pineal gland extracts he had been studying since the 1970s.

Does epitalon need to be injected?▼

Subcutaneous injection is the standard administration route. Some suppliers offer nasal spray formulations, but absorption and bioavailability through nasal mucosa for this peptide have not been validated in published research. For injection basics, see our guide on peptide injections.

References

1. Khavinson VK, Kopylov AT, Vaskovsky BV, et al. Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland. Bull Exp Biol Med. 2017;164(1):41-43. PubMed
2. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PubMed
3. Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. PubMed
4. Khavinson V, Diomede F, Mironova E, et al. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609. PubMed
5. Khavinson VKh, Tarnovskaya SI, Linkova NS, et al. Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med. 2013;154(3):403-410. PubMed
6. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PubMed
7. Caputi S, Trubiani O, Sinjari B, et al. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019;33:2058738419828613. PubMed
8. Lin’kova NS, Drobintseva AO, Orlova OA, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med. 2016;161(1):175-178. PubMed
9. Chalisova NI, Lin’kova NS, Zhekalov AN, et al. Short peptides stimulate skin cell regeneration during ageing. Adv Gerontol. 2014;27(4):699-703. PubMed
10. Khavinson VKh, Kuznik BI, Tarnovskaia SI, Lin’kova NS. Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data. Adv Gerontol. 2014;27(3):399-406. PubMed